CardioVascular Dynamics Wins U.S. Patient Approval for Rail-Design Microcatheters.IRVINE, Calif.--(BUSINESS WIRE)--Feb. 21, 1996--CardioVascular Dynamics, Inc. (CVD CVD Cardiovascular disease, see there ) subsidiary of EndoSonics Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ESON ESON Ethernet Switched Optical Network (Alamedia Networks) ESON Ethnobotanical Society of Nepal ) announced today that it has been notified by the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patent Office that a patent application for the Company's site-specific, drug delivery microcatheter technology will issue immediately. This patent entitled "Low Profile Infusion Catheter catheter /cath·e·ter/ (kath´e-ter) 1. a tubular, flexible surgical instrument that is inserted into a cavity of the body to withdraw or introduce fluid. 2. urethral c. " covers the utilization of CVD's patented Multiple Microporous Membrane (M3) Technology to provide greater access to remote anatomical anatomical /ana·tom·i·cal/ (an?ah-tom´i-kal) pertaining to anatomy, or to the structure of an organism. an·a·tom·i·cal or an·a·tom·ic adj. 1. Concerned with anatomy. 2. locations within the body and precise and accurate delivery of therapeutic solutions. CVD's M3 Technology also provides superior flexibility for maximum catheter performance in accessing difficult-to-reach locations in the body's anatomy. This is the first patent issued to CVD for the use of its M3 Technology for specific clinical applications. This patent includes the use of this technology for coronary, peripheral vascular, and neurovascular applications, as well as urological and site-specific delivery of chemotherapeutic drugs for cancer treatment. The issuance of this patent coincides with the worldwide product launch of the Company's Bullett Microcatheters. The Bullett microcatheters utilize a number of claims approved in this patent, including specific claims regarding both over-the-wire and rail-design versions of this technology. Commenting on the significance of this patent, CardioVascular Dynamics Chairman Michael Henson Michael Henson is a Cincinnati based teacher, activist and writer. Born April 14, 1947 in Sidney, Ohio he moved to Cincinnati to attend Xavier University where he majored in English. He later received a masters in English from University of Chicago. said, "This is a fundamental patent for site-spcific drug delivery utilizing technology providing both over-the-wire and rail-design catheter technology. We expect this patent to provide significant proprietary protection for our Bullett microcatheters. The initial shipments of Bullett catheters will begin in this quarter." CVD develops and markets site-specific drug delivery catheters, combined angioplasty-drug delivery catheters and advanced therapeutic catheters. All CVD products are manufactured in its Irvine, Calif. facilities. CONTACT: CardioVascular Dynamics, Inc. Heather Murray, 510/734-0464 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion